ICYMI: Lack Of Competition In Drug Market Drives Up Medicare & Medicaid Spending

03-18-2019 Blog Posts

In case you missed it, the Centers for Medicare and Medicaid Services (CMS) released new data last week which showed that prescription drugs with only one manufacturer are responsible for the biggest spending increases in both Medicare and Medicaid. According to the data, overall spending on prescription drugs under Medicare Part D increased at an […]

Good Medicine: Congress Should Pass Market-Based Solutions to Spur Prescription Drug Competition

03-13-2019 Blog Posts

The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act and the Fair Access for Safe and Timely (FAST) Generics Act are being discussed in a legislative hearing today before the U.S. House Energy & Commerce Subcommittee on Health.  The solutions contained in these market-based measures represent critical steps toward lowering prescription drug prices […]

Second Opinion: Rebate Rule Will Hike Premiums On Seniors

03-12-2019 Blog Posts

Lowering prescription drug prices is a laudable focus of the Trump Administration, and the Campaign for Sustainable Rx Pricing (CSRxP) supports several measures put forward by the administration, including getting more generics and biosimilars into the market to spur competition, increasing drug price transparency and cracking down on anti-competitive practices from big pharmaceutical manufacturers. But […]

Headlines: Lawmakers, Patients, Experts Keep-Up Drumbeat For Action On Drug Prices

03-9-2019 Blog Posts

Three More Congressional Hearings Tackle Big Pharma’s Anti-Competitive Practices   This week, the U.S. Senate Special Committee on Aging, U.S. House Ways & Means Subcommittee on Health and U.S. House Judiciary Subcommittee on Antitrust kept up the pace of activity on prescription drug pricing with a series of hearings on the issue. Members of Congress […]

ICYMI: House Judiciary Subcommittee on Anti-Trust Members Tout Benefits of CREATES Act

03-8-2019 Blog Posts

During today’s House Judiciary Subcommittee on Anti-trust hearing on healthcare consolidations – Members of Congress recognized Big Pharma’s continued role in price gouging American patient through patent abuse schemes to hinder generic competition and maintain monopolies over their biggest money makers. Importantly, key members of the committee used the hearing as an opportunity to tout the benefits […]

The Truth About Big Pharma’s Patent Abuse

03-6-2019 Blog Posts

Big Pharma is able to price gouge patients and avoid accountability. For decades, drug makers have gamed the patent system to block out competition and protect their profits – maintaining monopolies and driving up prices without making improvements to the medications patients need most.   Take a look:   Of the 100 best selling drugs, […]

Headlines: Big Pharma Reboots Tired Tactics During Hill Grilling

02-28-2019 Blog Posts

Testimony from Seven Drug Makers Showcases Continued Unwillingness to Take Responsibility, Become Part of the Solution On Tuesday, executives from seven of the biggest pharmaceutical companies in the world – including AbbVie, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Sanofi, AstraZeneca and Merck – testified before the Senate Committee on Finance on the crisis of […]


02-26-2019 Blog Posts

Big Pharma’s True Track Record Is A Hard Pill To Swallow Looking back at Big Pharma’s track record of broken proclamations, pledges and promises, it’s clear drug makers are not committed to turning their rosy rhetoric into reality for struggling American patients. With one in four Americans unable to afford their medications, it’s time Big […]

DOSE OF REALITY: Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part VII

02-25-2019 Blog Posts

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]

Big Pharma must be held accountable for insulin price crisis

02-23-2019 Blog Posts

By Sarah Gleich Saturday, Feb. 23, 2019 I have had diabetes since I was 5 years old. Like millions of people with diabetes, I rely on insulin 24 hours a day to survive. People like us are fighting for our lives due to the skyrocketing price of insulin. Year after year, the price goes up, […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.